Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Biology and Environment (15)
- (-) Clean Energy (23)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (2)
- Computational Engineering (1)
- Computer Science (1)
- Isotopes (1)
- Materials (15)
- Materials for Computing (1)
- National Security (14)
- Neutron Science (8)
- Quantum information Science (1)
- Supercomputing (20)
News Topics
- (-) Bioenergy (19)
- (-) Biomedical (7)
- (-) Cybersecurity (4)
- (-) Machine Learning (5)
- 3-D Printing/Advanced Manufacturing (30)
- Advanced Reactors (4)
- Artificial Intelligence (5)
- Big Data (2)
- Biology (18)
- Biotechnology (6)
- Buildings (8)
- Chemical Sciences (11)
- Clean Water (1)
- Climate Change (12)
- Composites (6)
- Computer Science (14)
- Coronavirus (8)
- Critical Materials (4)
- Decarbonization (11)
- Energy Storage (26)
- Environment (24)
- Exascale Computing (2)
- Fossil Energy (1)
- Frontier (1)
- Fusion (3)
- Grid (9)
- High-Performance Computing (6)
- Isotopes (4)
- Materials (19)
- Materials Science (13)
- Mercury (1)
- Microscopy (4)
- Molten Salt (1)
- Nanotechnology (6)
- National Security (4)
- Net Zero (2)
- Neutron Science (11)
- Nuclear Energy (10)
- Partnerships (8)
- Physics (2)
- Polymers (5)
- Quantum Science (1)
- Renewable Energy (1)
- Security (3)
- Simulation (5)
- Space Exploration (2)
- Summit (5)
- Sustainable Energy (26)
- Transformational Challenge Reactor (3)
- Transportation (17)
Media Contacts
Scientists studying a valuable, but vulnerable, species of poplar have identified the genetic mechanism responsible for the species’ inability to resist a pervasive and deadly disease. Their finding, published in the Proceedings of the National Academy of Sciences, could lead to more successful hybrid poplar varieties for increased biofuels and forestry production and protect native trees against infection.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.